FR11C0035I1 - - Google Patents

Info

Publication number
FR11C0035I1
FR11C0035I1 FR11C0035C FR11C0035I1 FR 11C0035 I1 FR11C0035 I1 FR 11C0035I1 FR 11C0035 C FR11C0035 C FR 11C0035C FR 11C0035 I1 FR11C0035 I1 FR 11C0035I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR11C0035(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of FR11C0035I1 publication Critical patent/FR11C0035I1/fr
Application filed filed Critical
Application granted granted Critical
Publication of FR11C0035I2 publication Critical patent/FR11C0035I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
FR11C0035C 1996-05-20 2011-09-02 Suspensions aqueuses d'esters d'acides gras de 9-hydroxyrisperidone Active FR11C0035I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20
PCT/EP1997/002504 WO1997044039A1 (en) 1996-05-20 1997-05-12 Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
EP97923912A EP0904081B1 (en) 1996-05-20 1997-05-12 Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters

Publications (2)

Publication Number Publication Date
FR11C0035I1 true FR11C0035I1 (cs) 2011-07-10
FR11C0035I2 FR11C0035I2 (fr) 2013-08-16

Family

ID=8224016

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0035C Active FR11C0035I2 (fr) 1996-05-20 2011-09-02 Suspensions aqueuses d'esters d'acides gras de 9-hydroxyrisperidone

Country Status (37)

Country Link
US (1) US6077843A (cs)
EP (1) EP0904081B1 (cs)
JP (1) JP3274687B2 (cs)
KR (1) KR100358373B1 (cs)
CN (1) CN1093762C (cs)
AR (1) AR007194A1 (cs)
AT (1) ATE208619T1 (cs)
AU (1) AU715572B2 (cs)
BG (1) BG62684B1 (cs)
BR (1) BR9706824B8 (cs)
CA (1) CA2236691C (cs)
CY (2) CY2270B1 (cs)
CZ (1) CZ291284B6 (cs)
DE (2) DE69708284T2 (cs)
DK (1) DK0904081T3 (cs)
EA (1) EA000536B1 (cs)
EE (1) EE03594B1 (cs)
ES (1) ES2167745T3 (cs)
FR (1) FR11C0035I2 (cs)
HR (1) HRP970276B1 (cs)
HU (2) HU224025B1 (cs)
ID (1) ID16927A (cs)
IL (1) IL124551A (cs)
LU (1) LU91842I2 (cs)
MX (1) MX9804816A (cs)
MY (1) MY126302A (cs)
NO (2) NO315931B1 (cs)
NZ (1) NZ330369A (cs)
PL (1) PL188309B1 (cs)
PT (1) PT904081E (cs)
SI (1) SI0904081T1 (cs)
SK (1) SK284013B6 (cs)
TR (1) TR199800923T2 (cs)
TW (1) TW487572B (cs)
UA (1) UA61898C2 (cs)
WO (1) WO1997044039A1 (cs)
ZA (1) ZA974331B (cs)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ATE265846T1 (de) * 1998-02-25 2004-05-15 Abbott Lab Butorphanol enthaltende formulierungen mit verzögerter freisetzung
WO2000010572A1 (en) * 1998-08-18 2000-03-02 Sepracor Inc. Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine
SI1169024T1 (sl) 1999-03-31 2006-06-30 Janssen Pharmaceutica Nv Predzelatinirani skrob v formulaciji s kontroliranim sproscanjem
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
KR100818875B1 (ko) * 2000-08-14 2008-04-01 테바 파마슈티컬 인더스트리즈 리미티드 리스페리돈의 제조
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
RU2321391C2 (ru) * 2002-07-29 2008-04-10 Алза Корпорейшн Способы и лекарственные формы для контролируемой доставки палиперидона
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
NZ546063A (en) 2003-10-23 2009-05-31 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole (7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]-butoxy]-3,4-dihydro-2(1H)-quinolinone) formulation and method
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
JP5306599B2 (ja) * 2004-01-12 2013-10-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 長期間送達製剤
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006114384A1 (en) 2005-04-25 2006-11-02 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
WO2008128436A1 (fr) * 2007-04-19 2008-10-30 Youxin Li Nouveaux composés pour le traitement de troubles psychotiques, procédés d'élaboration, et leurs utilisations
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
LT2234617T (lt) * 2007-12-19 2021-05-25 Janssen Pharmaceutica Nv Dozės režimai, susiję su ilgo veikimo injekuojamais paliperidono esteriais
US20090209757A1 (en) * 2008-01-10 2009-08-20 Santiago Ini Processes for the preparation and purification of paliperidone palmitate
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
CN104248623B (zh) 2008-09-04 2020-04-03 安米林药品有限责任公司 使用非水性载体的持续释放制剂
CA2775676C (en) 2009-09-28 2016-08-16 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
KR20120116401A (ko) 2009-10-30 2012-10-22 얀센 파마슈티카 엔.브이. 장기-작용성의 주사가능한 팔리페리돈 에스테르와 관련된 투약 요법
US20120259116A1 (en) * 2009-12-17 2012-10-11 Rajiv Kumar Novel Process for the Preparation of Paliperidone
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
JP5893616B2 (ja) 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
PL2683717T3 (pl) 2011-05-31 2016-11-30 Wytwarzanie 3-[2-[4-((6-fluoro-1,2-benzoizoksazol-3-ilo)-1-piperydynylo)-6,7,8,9-tetrahydro-9- hydroksy-2-metylo-4H-pirydo[1,2-a]pirymidyn-4-onu (paliperydonu) i palmitynianu paliperydonu
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3744326B1 (en) 2015-04-07 2023-12-06 Janssen Pharmaceutica NV Dosing regimen for missed doses for long-acting injectable paliperidone esters
CN107920884B (zh) 2015-06-03 2021-08-27 因塔西亚制药公司 植入物放置和移除系统
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US10835580B2 (en) 2017-01-03 2020-11-17 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
MX2023006370A (es) 2020-11-30 2023-08-07 Janssen Pharmaceutica Nv Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
FI4005555T3 (fi) 2020-11-30 2024-06-18 Janssen Pharmaceutica Nv Menetelmiä paliperidonipalmitaattiformulaatioiden uudelleensuspendoinnin varmistamiseksi
IL303252A (en) 2020-11-30 2023-07-01 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
SMT202400077T1 (it) 2020-11-30 2024-03-13 Janssen Pharmaceutica Nv Regimi di dosaggio associati con formulazioni iniettabili di paliperidone a rilascio prolungato
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
EP4137136A1 (en) 2021-08-20 2023-02-22 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
EP0729353B2 (en) * 1993-11-19 2012-09-12 Alkermes, Inc. Preparation of biodegradable microparticles containing a biologically active agent
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
DK0729357T3 (da) * 1993-11-19 2005-06-06 Janssen Pharmaceutica Nv Mikroindkapslede 1,2-benzazoler
WO1996039405A1 (en) * 1995-06-06 1996-12-12 Hoechst Marion Roussel, Inc. Pyridiniminyl-1,2-benzisoxazoles and- benzisothiazoles as antipsychotic agents
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Also Published As

Publication number Publication date
CZ291284B6 (cs) 2003-01-15
CY2270B1 (en) 2003-07-04
DE69708284T2 (de) 2002-07-25
DK0904081T3 (da) 2002-02-25
NO2011015I2 (no) 2013-03-11
HUS1100013I1 (hu) 2017-03-28
BR9706824B8 (pt) 2015-02-18
DE122011100027I1 (de) 2011-11-17
AU2955997A (en) 1997-12-09
NZ330369A (en) 2000-04-28
TW487572B (en) 2002-05-21
FR11C0035I2 (fr) 2013-08-16
ID16927A (id) 1997-11-20
SK62098A3 (en) 2000-04-10
CN1206347A (zh) 1999-01-27
KR19990067603A (ko) 1999-08-25
CA2236691C (en) 2007-01-02
PL188309B1 (pl) 2005-01-31
MY126302A (en) 2006-09-29
MX9804816A (es) 1998-10-31
PL327995A1 (en) 1999-01-04
CY2011011I2 (el) 2016-12-14
CA2236691A1 (en) 1997-11-27
EE9800136A (et) 1998-10-15
HUP9901319A3 (en) 1999-11-29
HRP970276A2 (en) 1998-04-30
ES2167745T3 (es) 2002-05-16
HRP970276B1 (en) 2002-04-30
NO2011015I1 (no) 2011-09-19
HK1017852A1 (en) 1999-12-03
US6077843A (en) 2000-06-20
BG62684B1 (bg) 2000-05-31
CZ140198A3 (cs) 1999-04-14
HUP9901319A2 (hu) 1999-08-30
AU715572B2 (en) 2000-02-03
BG102443A (en) 1999-06-30
JP2000513718A (ja) 2000-10-17
BR9706824A (pt) 1999-03-23
ZA974331B (en) 1998-11-19
SI0904081T1 (en) 2002-04-30
DE69708284D1 (de) 2001-12-20
TR199800923T2 (xx) 1999-09-21
PT904081E (pt) 2002-04-29
JP3274687B2 (ja) 2002-04-15
EP0904081A1 (en) 1999-03-31
CN1093762C (zh) 2002-11-06
EE03594B1 (et) 2002-02-15
NO981984L (no) 1998-11-19
ATE208619T1 (de) 2001-11-15
NO981984D0 (no) 1998-04-30
SK284013B6 (sk) 2004-08-03
EA199800531A1 (ru) 1998-12-24
EA000536B1 (ru) 1999-10-28
UA61898C2 (en) 2003-12-15
AR007194A1 (es) 1999-10-13
KR100358373B1 (ko) 2003-02-11
IL124551A0 (en) 1998-12-06
NO315931B1 (no) 2003-11-17
LU91842I2 (fr) 2011-09-20
CY2011011I1 (el) 2016-12-14
IL124551A (en) 2001-08-26
EP0904081B1 (en) 2001-11-14
WO1997044039A1 (en) 1997-11-27
HU224025B1 (hu) 2005-05-30

Similar Documents

Publication Publication Date Title
AR026662A2 (cs)
BRPI9713914B8 (cs)
FR11C0035I1 (cs)
IN192461B (cs)
IN188626B (cs)
IN191983B (cs)
ITMI960327A0 (cs)
ITMI960295A0 (cs)
IN191896B (cs)
IN191980B (cs)
BR7600721U (cs)
BR7601346U (cs)
IN189638B (cs)
ITAN960029V0 (cs)
ITMC960029V0 (cs)
BR9603859A (cs)
IN183780B (cs)
CN3044349S (cs)
CN3040550S (cs)
EP0909131A4 (cs)
CN3039213S (cs)
CN3044347S (cs)
EP0896572A4 (cs)
EP0802612A3 (cs)
CN3046158S (cs)